FDA Clears Median Technologies’ Lung Nodule Evaluation Software

FDA Issues 510(k) Clearance for AI-Powered Lung Cancer Detection on Low-Dose CT Scans

For the detection of lung cancer on low-dose CT, the eyonis LCS software reportedly offers greater than 90 percent sensitivity, specificity and negative predictive value (NPV).

FDA clears Median Technologies’ lung nodule evaluation software

Median's eyonis LCS is software is reimbursable under Medicare at a rate between $601 to $700.The post FDA clears Median Technologies’ lung nodule evaluation software appeared first on Medical Device Network.

Median Technologies Receives FDA 510(k) Clearance for eyonis® LCS, the First AI Tech-Based Detection and Diagnosis Device for Lung Cancer Screening

eyonis® LCS aims to redefine lung cancer screening by supporting diagnosis at early, curable stages, while reducing false positives to avoid unnecessary follow-up procedures, and has the potential to help save hundreds of thousands of lives in the US... L'articolo Median Technologies Receives FDA 510(k) Clearance for eyonis® LCS, the First AI Tech-Based Detection and Diagnosis Device for Lung Cancer Screening è un contenuto originale di 01net.